RxDoctor Payments Data

Daniel Kaswan, MD

Infectious Disease · Aventura, FLNPI 1942326418

Payments from drug & device makers

$21,280in general payments, 2019–2025

Across 126 payments — averaging $168.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$20K
  • Viiv Healthcare Company$611
  • Gilead$140
  • Johnson & Johnson$118
  • Shionogi Inc$92
  • Paratek Pharmaceuticals, Inc.$62
  • plus $116 from 3 others

What the payments were for

  • Speaking & faculty fees$18,18885%
  • Travel & lodging$6323%
  • Food & beverage$2,46112%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,280 in reported general payments places this provider in the 85th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$181,055
Medicare patients
630
Services billed
1,877

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala106$413,711
DovatoDolutegravir Sodium/Lamivudine80$244,009
TriumeqAbacavir/Dolutegravir/Lamivudi61$227,834
CabenuvaCabotegravir/Rilpivirine20$133,876
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf21$112,404
TivicayDolutegravir Sodium31$73,826
DescovyEmtricitabine/Tenofov Alafenam24$54,149
GenvoyaElviteg/Cob/Emtri/Tenof Alafen13$50,721
Isentress HdRaltegravir Potassium13$25,341
ErtapenemErtapenem Sodium11$9,143
Cefepime Hcl26$7,717
Cefazolin Sodium21$1,012
CeftriaxoneCeftriaxone Sodium11$598
Methenamine Hippurate13$545
Cefadroxil23$458

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Triumeq, Cabenuva, Tivicay$611$679,545192 claims
GileadBiktarvy, Descovy, Genvoya$140$518,581143 claims
MerckIsentress Hd$58$25,34113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Aventura

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →